Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ChAdOx1 MERS vaccine safety and immunogenicity in Middle Eastern adults
NCT04170829Phase 1Completed
- Sponsor
- King Abdullah International Medical Research Center
- Start
- Dec 2019
- Primary completion
- Nov 2020
- Modality
- Prophylactic Vaccines, Viral Vectors, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of ChAdOx1 MERS in Middle East respiratory syndrome (MERS), sponsored by King Abdullah International Medical Research Center. Started Dec 2019; status: completed.
02
Drugs
ChAdOx1 MERS
03
Conditions
Middle East respiratory syndrome (MERS)
Beyond the preview
Go deeper on NCT04170829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04170829.